Anticonvulsant agent 7

Cat. No.: HY-170801: Data Sheet Handling Instructions
FAQs
Technical Support

Anticonvulsant agent 7 is an orally active, broad-spectrum anticonvulsant that does not rely on direct blockade of Na⁺/Ca²⁺ channels. Anticonvulsant agent 7 can be used in seizure research^[1].

For research use only. We do not sell to patients.

Anticonvulsant agent 7 Chemical Structure

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All Calcium Channel Isoform Specific Products:

View All Isoforms

N-type calcium channel L-type calcium channel P/Q-type calcium channel T-type calcium channel Calcium Channel

View All Sodium Channel Isoform Specific Products:

View All Isoforms

Na_v1.1 Na_v1.2 Na_v1.3 Na_v1.4 Na_v1.5 Na_v1.6 Na_v1.7 Na_v1.8 Na_v1.9

Biological Activity
Purity & Documentation
References
Customer Review

Description

Anticonvulsant agent 7 is an orally active, broad-spectrum anticonvulsant that does not rely on direct blockade of Na⁺/Ca²⁺ channels. Anticonvulsant agent 7 can be used in seizure research^[1].

In Vivo

Anticonvulsant agent 7 (Compound 19) (30-300 mg/kg; i.p.; single administration) fully protects mice against MES (tonic-clonic seizure)-induced seizures, with an ED₅₀ of 26.3 mg/kg and a protective index > 3.8^[1].
Anticonvulsant agent 7 (30-300 mg/kg; i.p.; single administration) protects mice against scPTZ (absence/myoclonic)-induced seizures^[1].
Anticonvulsant agent 7 (i.p.; single administration) has an ED₅₀ of 11.1 mg/kg against psychomotor seizures induced by 6 Hz (32 mA), with a protective index > 9.0^[1].
Anticonvulsant agent 7 (i.p.; single administration) has an ED₅₀ of 40.9 mg/kg against drug-resistant seizures induced by 6 Hz (44 mA), with a protective index > 2.5^[1].
Anticonvulsant agent 7 (30 mg/kg; p.o.; single administration) protects up to 100% of rats against MES-induced seizures, with the peak protective effect achieved at 0.5 h post-administration^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	CF1 mice (male); CD-1 mice (male, 20-26 g)^[1]
Dosage:	30 mg/kg; 100 mg/kg; 300 mg/kg (preliminary screening); 26.3 mg/kg (ED₅₀ determination)
Administration:	i.p.; single dose
Result:	Protected 100% of mice at 0.5 h and 4 h post-administration. Achieved a median effective dose (ED₅₀) of 26.3 mg/kg (i.p.). Demonstrated a protective index (PI) of >3.8 relative to neurotoxicity (TD₅₀ >100 mg/kg).

Animal Model:	CF1 mice (male); CD-1 mice (male, 20-26 g)^[1]
Dosage:	30 mg/kg; 100 mg/kg; 300 mg/kg
Administration:	i.p.; single dose
Result:	Protected 100% of mice at 0.5 h and 4 h post-administration at 100 mg/kg (i.p.).

Animal Model:	Sprague-Dawley rats (male, albino)^[1]
Dosage:	30 mg/kg
Administration:	p.o.; single dose
Result:	Protected 50% of rats at 0.25 h post-administration. Protected 100% of rats at 0.5 h post-administration. Protected 75% of rats at 1 h post-administration. Protected 50% of rats at 2 h post-administration. Protected 50% of rats at 3 h post-administration.

Molecular Weight

317.38

Formula

C₁₇H₂₃N₃O₃

SMILES

O=C1N(CN2CCOCC2)C(C(C3=CC=CC=C3)(C(C)C)N1)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Czopek A, Byrtus H, Góra M, et al.. Synthesis, Anticonvulsant, Antinociceptive Activity and Preliminary Safety Evaluations of Novel Hybrid Imidazolidine-2,4-Dione Derivatives with Morpholine Moiety. ChemMedChem. 2025 Apr 01;20(7):e202400612. [Content Brief]